Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Humanized antibody Stories

2008-11-11 09:00:47

MORRIS PLAINS, N.J., Nov. 11, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Gerard G. Gorman, Senior Vice President, Finance and Business Development, and Chief Financial Officer, will be presenting at the Lazard Capital Markets 5th Annual Healthcare Conference to be held in New York City from November 18 - 19, 2008. Mr. Gorman's presentation,...

2008-10-30 09:00:41

MORRIS PLAINS, N.J., Oct. 30, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that Cynthia L. Sullivan, President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer 19th Annual Healthcare Conference in New York. The presentation, scheduled on November 4, 2008 at 4:00 p.m., can be downloaded simultaneously at...

2008-10-28 12:00:17

Seattle Genetics, Inc. (Nasdaq: SGEN) today presented preclinical data on SGN-70 at the American College of Rheumatology (ACR) Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody targeting CD70 that is in development as a novel therapy for autoimmune diseases. Seattle Genetics is currently conducting a phase I trial to assess the safety, tolerability and pharmacokinetics of SGN-70 in healthy volunteers. "CD70 is an ideal target for...

2008-10-25 21:00:20

BERKELEY, Calif., Oct. 25, 2008 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that its poster titled "Efficacy Of XOMA 052 Anti-IL-1 Beta Antibody In The DBA/1 Mouse Collagen-Induced Arthritis Model" will be presented at the American College of Rheumatology 2008 Annual Conference, on Sunday, October 26 from 9:00 AM until 11:00 AM in Hall A. The poster also contains data demonstrating that XOMA 052 blocks...

2008-10-15 12:00:34

Immunomedics, a biopharmaceutical company, has received a new US patent that covers the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on B-lymphocytes, leukemias, and lymphomas. The allowed claims cover the use of veltuzumab and bispecific antibody protein constructs for the treatment and diagnosis of B-cell disorders,...

2008-10-14 09:00:11

MORRIS PLAINS, N.J., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, announced that U.S. patent 7,435,803 was issued today covering the composition of matter and the use of humanized, chimeric and human anti-CD20 antibodies and antibody fusion proteins or fragments thereof comprising at least the veltuzumab antibody that targets the CD20 antigen present on...

2008-10-02 09:00:07

DALLAS, Oct. 2 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (BULLETIN BOARD: ACCP) presented data this week from preclinical studies on Angiolix showing that by blocking lactadherin, Angiolix has both an anti-angiogenic effect as well as a direct anti-proliferative effect on tumors themselves. In preclinical models of human breast cancer (MX-1), Angiolix had a significant anti-cancer effect in vivo; this effect was enhanced when Angiolix was given in combination with...

2008-09-26 09:00:40

4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschaeftsfuehrer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence. Previously Dr. Mason was Senior Vice President Business Development at Cambridge Antibody Technology plc (CAT). As head of CAT's business development team he was responsible for numerous transactions with major...

2008-08-07 18:01:54

BERKELEY, Calif., Aug. 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its results for the quarter ended June 30, 2008. "In the second quarter of 2008, XOMA made clear progress in its proprietary clinical programs, presented related data at two major medical conferences, increased its cash balance, and grew its royalty revenues," said Steven Engle, Chairman and Chief Executive Officer of XOMA. "The...

2008-08-05 09:01:31

CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today that Genentech, a collaborator, has moved a modified version of TRX1, MTRX1011A, an anti-CD4 monoclonal antibody, into a phase 1 clinical trial that has begun enrolling patients. The clinical trial is evaluating the safety and tolerability of both single and multiple doses of MTRX1011A....